DOC1021 Dendritic Cell Immunotherapy

DOC1021 · Diakonos Oncology Corporation

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for DOC1021 Dendritic Cell Immunotherapy, covering 2026-04-14 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) [Phase 2]